Chuck Akre On The Search For Compounding Machines by Russel Kinnel

Get The Full Seth Klarman Series in PDF

Get the entire 10-part series on Seth Klarman in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues.

We respect your email privacy

We talked with Chuck Akre who built an outstanding record subadvising FBR Focus before the two split and Akre launched a new fund, Akre Focus AKREX. He runs a concentrated growth style that really is unlike anything else you'll find.

Russ Kinnel: Can you tell us a little about how you built the team up and who is there?

Chuck Akre: I started off Akre Capital Management in 1989. So, we do have a new fund, which became effective Aug. 31 of 2009. The analysts who had worked with me on the fund and other things and the prior fund left, and we built a new team. In October of 2009, we added Tom Saberhagen, who had been a senior analyst at the Aegis Value fund. In November of 2009, we added John Neff who had been a senior analyst on the sell-side at William Blair. Then in September of 2010, we added Andrew Osborne, who falls in sort of the rookie category. I thought he had great instincts and done quite a lot of work in the investment business as an independent thinker.

Kinnel: Does each analyst have sector specialties or are they generalists?

Chuck Akre: Well, they are indeed generalists, but quite naturally their areas of expertise are slightly different. Tom has an undergraduate degree from Rice and an MBA from Stanford. Tom's background in the fund business was deep-value shop, and John's undergraduate study was at Colgate and then he attended Booth School at the University of Chicago. He came from a growth shop at William Blair. So, the stocks they follow tend to fall into the value and growth camps, respectively. The more richly valued companies are typically little higher growers, faster growth rates, and those are generally things that John is involved in, and Tom has been involved in things which are a little bit more modestly valued and more traditional in their nature.

Kinnel: You've said you look for "compounding machines." Would you explain what that means?

Chuck Akre: When I started in the investment business a good while ago, I was not trained for itin a traditional sense. I had been a premed  major, and then I was an English major. So, I quite naturally had all kinds of questions about the investment business, and among them were the questions of what makes a good investor and what makes a good investment, and taking a look and studying different asset classes using data from what is now your subsidiary Ibbotson and other places. I came across the well-known piece of information that over the last roughly 90 years common stocks in the United States have had an annualized return that's in the neighborhood of 10%.

So, my question naturally was, well, what's important about 10%? What I concluded was that it had a correlation with what I believe was the real return on the owners' capital of all those businesses across all those years, all kinds of different balance sheets and business models -- i.e., that the real return on owners' capital was a number that was probably in the low teens and therefore that kind of 10%ish return correlated with that, and it caused me to posit that my return in an asset would approximate the ROE of a business given the absence of any distributions and given constant valuation. So, then, we say, well, if our goal is to have returns which are better than average, while assuming what we believe is the below-average level of risk, then the obvious way to get there is to have businesses that have returns on the owners' capital which are above that.

Early in the 1970s, I came across a book written by a Boston investment counselor, whose name was Thomas Phelps. And the book he wrote was called 100 to 1 in the Market. You probably know from the history books that Peter Lynch was around Boston in those days, and he was talking about things like "10Baggers." But here was Thomas Phelps, who was talking about "100 to 1." He documented characteristics of these businesses that caused one to have an experience, where they could make 100 times their investment. The answer is, of course, it's an issue at the rate at which they compounded the shareholders' capital on a per unit of ownership basis and those that compounded the shareholders' equity at a higher rate had higher returns over long period of years. And so that's what comes into play is this issue of compounding compound machines, and we're often identified with this thing in our process that we call the three-legged stool. The legs of the stool have to do with the business models that are likely to compound the shareholders' capital at above-average rates, combined with leg two, people who run the business who are not only killers at running the business but also see to it that what happens at the company level also happens at the per share level-and then number three, where because of the nature of the business and the skill of the manager there is both history as well as an opportunity to reinvest all the excess capital they generate to reinvest that in places where they earn these above-average rates of return.

The most critical piece of that is the last leg, that reinvestment leg. Can you take all the extra capital you generate and reinvest it in ways that you can get continued earnings above-average rates of return? And that's at the core of what we're after in our investments.

Kinnel: On the sell-side, deterioration on those key fundamentals may lead you to sell, but do you also sell on valuation?

Chuck Akre: So, in response to your first observation, deterioration to any one of those three will certainly cause us to reevaluate it. It won't automatically cause us to sell, but it will certainly cause us to reevaluate it. Our notion is that if we don't get those three legs right where there develop differently in the future than they have in the past, theoretically our loss is the time value of money that it hasn't always been the case. But the deterioration of one of those legs or more than one of those legs diminishes the value of that compounding and, indeed, is likely to cause us to change our view. That's number one.

Number two, the issue of selling on valuation is way more difficult for us. And what we've said is that from a matter of life experience, if I have a stock that's at $40 and I think it's way too richly valued and I sell it with a goal of buying it back at $25, my life experience is it trades to $25.01 or trades through $25 and back up and it trades 200 shares there. The next time I look at it, it's $300, and I've missed the opportunity. It's my way of saying that the really good ones are too hard to find.

If I have one of these great compounders, I'm likely to continue to own it through thick and thin knowing that periodically, it's likely to be undervalued and periodically likely to be overvalued. The things

1, 2  - View Full Page